Insulin glargine 300 safe, effective in seniors with T2DM
Robert Ritzel, M.D., from Städtisches Klinikum München GmbH in Munich, Germany, and colleagues conducted a multicenter trial involving older adults, aged ≥65 years, designed to have about 20 percent of participants be aged ≥75 years. A total of 1,014 participants were randomly allocated to receive Gla-300 or Gla-100, titrated to a fasting self-monitored plasma glucose of 5 to 7.2 mmol/L.
The researchers found that from baseline to week 26, the reductions in HbA1c were comparable for Gla-300 and Gla-100 in the overall population and for participants aged ≥75 years. Similar and low incidence and rates of confirmed or severe hypoglycemia events were reported between the groups, with lower rates of documented symptomatic hypoglycemia with Gla-300. Compared with the overall population, the subgroup aged ≥75 years had a more apparent lower risk of hypoglycemia with Gla-300 versus Gla-100. The annualized rates of documented symptomatic hypoglycemia were significantly lower with Gla-300 (Gla-300, 1.12 versus Gla-100, 2.71; rate ratio, 0.45).
"Gla-300 demonstrated good efficacy and safety in older people with type 2 diabetes, particularly in those of advanced age (≥75 years)," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Sanofi, which funded the study and the clinical trial considered in the analysis.
Copyright © 2018 HealthDay. All rights reserved.